Find disease awareness content and relevant supporting materials

Antibodies targeting IL-1RA appeared earlier and at higher levels in some women who delivered preterm, suggesting a potential pathway for preventing some preterm births. Separately, a 280-procedure study found propofol requirements varied by cannabis product type, with higher average initial doses among patients who smoked or vaped cannabis.

Experimental ANB033 protected against intestinal damage and prevented increased symptoms during gluten exposure in a 32-patient celiac disease trial. Separately, studies found uncertain evidence of sleep benefits from medical cannabis and linked long-term cannabis use to poorer sleep, while an AI platform enabled epilepsy patients to interact with monitoring devices.

Researchers reported the first human use of a transcatheter coronary artery bypass procedure performed without opening the chest. Separately, new markers improved detection of circulating triple-negative breast cancer cells, and varenicline reduced cannabis use in men with cannabis use disorder.

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

In the last 30 years or so there has been increased attention on the medical uses of cannabis and its constituent chemicals. Cannabis itself contains at least 60 active cannabinoids, one of which, cannabidiol (CBD)...

The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

Samsung Bioepis Co. Ltd. announced that Health Canada has approved Ontruzant (also known as SB3), a biosimilar referencing Herceptin (Trastuzumab), for the treatment of adults with Early Breast Cancer (EBC), Metastatic Breast Cancer (MBC) and metastatic gastric cancer (MGC).